AstraZeneca and MSD’s Lynparza (olaparib) Receives EC’s Approval for BRCA-Mutated Metastatic Pancreatic Cancer

 AstraZeneca and MSD’s Lynparza (olaparib) Receives EC’s Approval for BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca and MSD’s Lynparza (olaparib) Receives EC’s Approval for BRCA-Mutated Metastatic Pancreatic Cancer

Shots:

  • The EC’s approval is based on P-III POLO study assessing Lynparza (300mg, bid) as maintenance monothx. vs PBO in 154 patients in a ratio (3:2) with gBRCAm metastatic pancreatic cancer whose disease had not progressed on 1L platinum-based CT
  • The study demonstrated that Lynparza nearly doubled the lifespan of patients without disease progression or death (7.4 vs 3.8 mos.). The safety and tolerability profile of Lynparza in the study was consistent with previous trials
  • The approval follows CHMP’s recommendation granted on Jun 01, 2020. Lynparza is a first-in-class PARP inhibitor acts by targeting DDR in cells/tumors harboring a deficiency in HRR (BRCA1& 2 mutation)and is approved in the US & other countries as a 1L maintenance treatment for patients with gBRCAm metastatic pancreatic cancer

Click here to read full press release/ article | Ref: AstraZeneca | Image: Pharmaceutical Technology

Related News: AstraZeneca’s Lynparza (olaparib) Receives MHLW’s Orphan Drug Designation for BRCA-Mutated Metastatic Pancreatic Cancer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post